Assessment of SGLT2 Inhibitor, Canagliflozin Effects on Metabolic Syndrome-Induced Cardiovascular Disorders in Rats

Reno Protective Effect of Sodium Glucose Cotransporter-2 Inhibitor (Dapagliflozin) in Type 2 Diabetic Patients

The Reno-protective effect of SGLT-2 inhibitors in non-diabetic patients. A comparative review

Comparison between the ameliorative potentials of canagliflozin and metformin on the testicular damage in diabetic rats

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats

Protective Effect of Sodium-Glucose Co-Transporter 2 Inhibitor (Dapagliflozin) on Diabetic Retinopathy in Streptozotocin Induced Diabetes in Rats

Effectiveness of canagliflozin with atorvastatin on dexamethasone-induced dyslipidemia and hepatic steatosis in albino rats

The Potential Ameliorative Effect of Empagliflozin on Myocardium in Cardiorenal Syndrome 3 via Targeting Mitophagy and Mitochondrial Biogenesis in Adult Male Albino Rat Model: Bi

POTENTIAL ROLE OF GLP-1 RECEPTOR AGONIST IN A RAT MODEL OF CARDIO-RENAL SYNDROME TYPE-3: EFFECTS ON OXIDATIVE, INFLAMMATORY AND INOS EXPRESSION AXIS

Dapagliflozin Ameliorates Glycemic State, Lipid Profile and Renal Functions in Type 2 Diabetic Rats